In another study, van Hauten and colleagues successfully transduced NK cells derived from CD34+ hematopoietic stem and progenitor cells with hnCD16, leading to enhanced ADCC in combination with the tumor-targeting antibody rituximab when tested in vitro towards tumor cell lines and primary leukemia cells [64]. The gene discussed is CD34; the disease is neoplasm.